Resmed
RMD
$195.27
+1.76%
ResMed is a global leader in respiratory care devices, primarily developing flow generators, masks, and accessories for sleep apnea treatment. The company holds a dominant market position in the sleep-disordered breathing space, benefiting from structurally growing demand driven by aging populations, rising obesity rates, and increased sleep apnea diagnosis. The current investor narrative centers on ResMed's digital health transformation and margin expansion, with recent acquisitions like Noctrix Health signaling a push into adjacent neurological conditions. However, the stock has faced headwinds from competitive pressures and a broader market rotation out of growth healthcare names.…
RMD
Resmed
$195.27
Related headlines
Investment Opinion: Should I buy RMD Today?
Rating: Buy. ResMed is a high-quality growth company trading at a discounted forward P/E of 16.6x, with strong revenue acceleration (10.8% YoY) and expanding margins (gross margin 62.2%). The analyst consensus is Buy with an average target of $252.20, implying 26.7% upside.
Supporting evidence: (1) Forward P/E of 16.6x is a 25% discount to the industry average of 22x. (2) Revenue growth accelerated to 10.8% YoY in Q3 FY2026 from 6.7% a year ago. (3) Net margin of 27.9% is nearly double the industry average. (4) Free cash flow of $1.748B TTM provides a 4.6% FCF yield. (5) PEG ratio of 0.72 indicates undervaluation relative to growth.
Risks & Conditions: The biggest risks are competitive pressure from Inspire Medical and potential reimbursement cuts. This Buy rating would be downgraded to Hold if revenue growth falls below 8% or gross margin drops below 60%. It would be upgraded to Strong Buy if the stock pulls back to $180 (52-week low) while fundamentals remain intact. Overall, ResMed is undervalued relative to its growth and profitability, offering a favorable risk/reward at current levels.
Sign up to view all
RMD 12-Month Price Forecast
ResMed's fundamental strength is compelling: accelerating revenue growth, expanding margins, and a fortress balance sheet. The forward P/E of 16.6x is cheap relative to both peers and history, and the PEG ratio of 0.72 suggests the market is not fully pricing in the growth trajectory. However, the stock's technical downtrend and recent analyst downgrades introduce uncertainty. The base case of reaching the average target of $252.20 (26.7% upside) is most likely, supported by consistent execution. The stance would be upgraded to high confidence if the stock breaks above its 200-day moving average or if Q4 earnings show further acceleration. It would be downgraded to neutral if revenue growth falls below 8% or if competitive threats materialize.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Resmed's 12-month outlook, with a consensus price target around $248.60 and implied upside of +27.3% versus the current price.
Average Target
$248.60
0 analysts
Implied Upside
+27.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$180 - $325
Analyst target range
ResMed is covered by 15 analysts, with a consensus recommendation of 'Buy' (mean score 2.33 on a 1-5 scale where 1 is Strong Buy). The average target price is $252.20, implying 26.7% upside from the current price of $198.99. The distribution leans bullish, with no sell ratings and a majority of buy-equivalent ratings. However, recent downgrades from Citigroup (Neutral) and Morgan Stanley (Equal Weight) suggest some caution. The target price range spans from a low of $180.00 to a high of $325.00. The high target of $325 assumes successful execution of digital health initiatives and margin expansion, while the low target of $180 reflects risks from competitive pressures and potential reimbursement cuts. The wide spread of $145 (45% of the average) indicates high uncertainty among analysts. Recent rating actions show a mix of reaffirmations (Mizuho Outperform, RBC Outperform) and downgrades (Citigroup to Neutral, Morgan Stanley to Equal Weight), signaling that while the long-term story remains intact, near-term headwinds are causing some analysts to temper expectations.
Drowning in data?
Find the real signal!
Bulls vs Bears: RMD Investment Factors
ResMed presents a compelling bull case based on accelerating revenue growth (10.8% YoY), expanding margins (gross margin 62.2%), and a fortress balance sheet (D/E 0.14). The forward P/E of 16.6x is at a discount to peers and its own history, supported by a PEG ratio of 0.72. However, the stock is in a persistent downtrend (-22.4% over 1 year) with recent analyst downgrades and a high short ratio of 9.46 days. The single most important tension is whether the company's strong operational performance can overcome negative market sentiment and competitive fears. If revenue growth sustains above 10% and margins continue to expand, the stock could re-rate higher; if growth decelerates or competitive pressures mount, the stock could test its 52-week low of $180.27. Currently, the bull case has stronger fundamental evidence, but the bearish technicals and sentiment warrant caution.
Bullish
- Strong Revenue Growth Acceleration: Revenue grew 10.8% YoY in Q3 FY2026 to $1.431B, accelerating from 6.7% growth in the prior year quarter. This demonstrates robust demand for sleep apnea devices and software, driven by aging populations and rising obesity rates.
- Expanding Margins and Profitability: Gross margin improved from 57.6% in Q4 FY2024 to 62.2% in Q3 FY2026, while operating margin reached 34.9%. Net margin of 27.9% is nearly double the medical devices industry average of ~15%, highlighting strong pricing power and operational efficiency.
- Fortress Balance Sheet with Low Debt: Debt-to-equity is only 0.14 and current ratio is 3.44, indicating minimal financial risk. Free cash flow of $1.748B TTM provides ample liquidity for organic investments and acquisitions like Noctrix Health.
- Attractive Forward Valuation: Forward P/E of 16.6x is at a 25% discount to the medical devices industry average of 22x, and well below its 5-year historical range of 20-49x. The PEG ratio of 0.72 suggests the stock is undervalued relative to its growth rate.
Bearish
- Persistent Price Downtrend: The stock has declined 22.4% over the past year, underperforming the S&P 500 by 40.7%. It trades at only 67.7% of its 52-week range, near the low of $180.27, indicating sustained negative sentiment.
- High Trailing P/E vs. Industry: Trailing P/E of 27.0x is a 23% premium to the medical devices industry average of 22x. This premium may be unjustified if growth decelerates or competitive pressures intensify.
- Recent Analyst Downgrades: Citigroup downgraded to Neutral and Morgan Stanley to Equal Weight, signaling near-term caution. The wide target spread ($180-$325) reflects high uncertainty about future performance.
- Competitive and Reimbursement Risks: Competitors like Inspire Medical and Philips are gaining share in sleep apnea. Potential Medicare reimbursement cuts or changes in coding could pressure pricing and volumes.
RMD Technical Analysis
ResMed is in a sustained downtrend, with the stock declining 22.4% over the past year compared to the S&P 500's gain of 18.4%. The current price of $198.99 sits at 67.7% of its 52-week range (low $180.27, high $293.81), reflecting a bearish posture near the lower end of the range. This positioning suggests the market is pricing in significant negative sentiment, though it could also represent a value opportunity if fundamentals stabilize. Short-term momentum shows a conflicting signal: the 1-month price change is +6.8%, while the 3-month change is -12.8%. This divergence indicates a potential short-term bounce within a longer-term downtrend, possibly driven by oversold conditions or temporary optimism around recent acquisitions. The relative strength versus the S&P 500 over 1 month is +6.5%, but over 1 year it is -40.7%, underscoring the persistent underperformance. The 52-week low of $180.27 provides key support, while the 52-week high of $293.81 is a major resistance level. A break above $293.81 would signal a trend reversal, while a drop below $180.27 could accelerate selling. With a beta of 0.78, ResMed is less volatile than the market, meaning its downtrend has been more orderly but also less likely to snap back quickly.
Beta
0.78
0.78x market volatility
Max Drawdown
-37.8%
Largest decline past year
52-Week Range
$180-$294
Price range past year
Annual Return
-28.6%
Cumulative gain past year
| Period | RMD Return | S&P 500 |
|---|---|---|
| 1m | -0.6% | +0.8% |
| 3m | -11.2% | +3.5% |
| 6m | -22.6% | +7.2% |
| 1y | -28.6% | +16.5% |
| ytd | -20.2% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RMD Fundamental Analysis
ResMed's revenue trajectory remains solidly growing, with the most recent quarter (Q3 FY2026) reporting $1.431 billion, up 10.8% year-over-year. This marks an acceleration from the prior year's Q3 growth of 6.7% (from $1.292 billion to $1.431 billion), driven by strong demand in the Sleep and Respiratory segment ($1.256 billion) and Residential Care Software ($167 million). The multi-quarter trend shows consistent sequential growth from $1.223 billion in Q4 FY2025 to $1.431 billion, indicating a healthy top-line expansion that supports the investment case for market share gains and pricing power. Profitability is robust, with net income of $398.7 million in Q3 FY2026, yielding a net margin of 27.9%. Gross margin has expanded from 57.6% in Q4 FY2024 to 62.2% in Q3 FY2026, reflecting operational leverage and favorable product mix. Operating margin of 34.9% is well above industry averages for medical devices, highlighting ResMed's pricing power and cost discipline. The company is consistently profitable with no signs of margin compression. ResMed boasts a fortress balance sheet: debt-to-equity of only 0.14, a current ratio of 3.44, and free cash flow of $1.748 billion over the trailing twelve months. The company generates ample cash to fund growth internally, with FCF yield of 4.6% based on current market cap. ROE of 23.5% underscores efficient capital allocation, and the low leverage suggests minimal financial risk.
Quarterly Revenue
$1.4B
2026-03
Revenue YoY Growth
+10.8%
YoY Comparison
Gross Margin
62.3%
Latest Quarter
Free Cash Flow
$1.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RMD Overvalued?
Since net income is positive ($398.7 million), we lead with the P/E ratio. The trailing P/E is 27.0x, while the forward P/E is 16.6x, implying the market expects significant earnings growth over the next year. The gap between trailing and forward P/E suggests analysts anticipate a sharp acceleration in EPS, likely driven by margin expansion and revenue growth. Compared to the medical devices industry average P/E of roughly 22x, ResMed's trailing P/E of 27.0x represents a 23% premium. However, the forward P/E of 16.6x is at a 25% discount to the industry forward average of 22x, indicating that the market is pricing in above-average growth expectations that have yet to materialize. This premium is justified by ResMed's superior net margin (27.9% vs. industry ~15%) and ROE (23.5% vs. industry ~18%). Historically, ResMed's trailing P/E has ranged from 20x to 49x over the past five years. The current 27.0x is near the lower end of that range, suggesting the stock is relatively cheap compared to its own history. This could indicate a value opportunity if the company's growth trajectory remains intact, or it could reflect structural concerns about competitive threats and market saturation.
PE
27.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 21x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: ResMed's financial risks are low given its debt-to-equity of 0.14, current ratio of 3.44, and TTM free cash flow of $1.748B. However, the company's net margin of 27.9% is high and could compress if pricing pressure intensifies or input costs rise. Revenue concentration in sleep apnea devices (roughly 88% of sales) exposes the company to market saturation or technological disruption. The recent acquisition of Noctrix Health for $340 million introduces integration risk, though the amount is manageable relative to FCF.
Market & Competitive Risks: The stock's trailing P/E of 27.0x is a 23% premium to the industry average, leaving it vulnerable to multiple compression if growth disappoints. Competitive threats from Inspire Medical (hypoglossal nerve stimulation) and Philips (recall recovery) could erode market share. Regulatory risks include potential Medicare reimbursement cuts for sleep apnea devices. The stock's beta of 0.78 provides some downside protection but also limits upside participation in market rallies. Recent downgrades from Citigroup and Morgan Stanley highlight near-term uncertainty.
Worst-Case Scenario: A combination of slower revenue growth (below 5%), margin compression from competitive pricing, and a broader market downturn could drive the stock to its 52-week low of $180.27, representing a 9.4% decline from the current price of $198.99. In a severe recession with healthcare spending cuts, the stock could fall to the analyst low target of $180.00, a 9.5% loss. The historical max drawdown of -37.76% suggests a worst-case decline to approximately $124, though this is unlikely given the company's strong fundamentals.
FAQ
The key risks are: (1) Competitive risk from Inspire Medical's hypoglossal nerve stimulation therapy, which could disrupt CPAP dominance. (2) Regulatory risk from potential Medicare reimbursement cuts for sleep apnea devices, which could pressure pricing. (3) Execution risk from the Noctrix Health acquisition ($340M) and integration of digital health initiatives. (4) Macro risk from a recession that could delay elective procedures and reduce device sales. The most severe risk is competitive disruption, which could compress margins and slow growth. The stock's beta of 0.78 provides some downside protection, but a prolonged downturn could test the 52-week low of $180.27.
The 12-month forecast is moderately bullish. The base case (50% probability) sees the stock reaching $220-$252, driven by 8-10% revenue growth and stable margins. The bull case (30% probability) targets $252-$325 if growth accelerates and margins expand. The bear case (20% probability) sees the stock falling to $180-$200 if growth decelerates or competitive pressures mount. The most likely scenario is the base case, with the stock reaching the analyst average target of $252.20, implying 26.7% upside. Key assumptions include sustained revenue growth above 8% and gross margins above 60%.
ResMed is undervalued based on forward metrics. The forward P/E of 16.6x is at a 25% discount to the medical devices industry average of 22x and well below its 5-year historical range of 20-49x. The PEG ratio of 0.72 indicates the stock is cheap relative to its expected earnings growth. However, the trailing P/E of 27.0x is a 23% premium to the industry, reflecting the market's expectation of strong future growth. On an EV/EBITDA basis, the stock trades at 19.6x, which is reasonable given its operating margin of 34.9%. Overall, the valuation is attractive for a company with ResMed's profitability and growth profile.
Yes, ResMed is a good stock to buy for investors seeking a high-quality growth company at a reasonable price. The stock offers 26.7% upside to the analyst average target of $252.20, supported by 10.8% revenue growth and a forward P/E of 16.6x — a 25% discount to the medical devices industry. The biggest downside risk is competitive pressure from Inspire Medical, which could slow growth. For long-term investors with a 3-5 year horizon, the risk/reward is favorable given the company's strong margins, low debt, and secular demand drivers. However, short-term traders should be cautious due to the stock's persistent downtrend and high short interest.
ResMed is best suited for long-term investment (3-5 years) due to its secular growth drivers in sleep apnea and digital health. The stock's beta of 0.78 indicates lower volatility than the market, making it a relatively stable long-term holding. The dividend yield of 0.82% is modest but growing, with a payout ratio of 22.2%. Short-term trading is riskier given the stock's 22.4% decline over the past year and high short interest (9.46 days to cover). The company's strong fundamentals and discounted valuation support a buy-and-hold strategy, with a suggested minimum holding period of 3 years to allow the growth story to play out.
